| Publisher’s Note: Break the silos. Spark the strategy. Fierce Pharma Engage brings every key function together to move brands forward. Learn how now! |
|
Monday, April 21, 2025 | 12pm ET / 9am PT Join us for an exclusive webinar exploring groundbreaking findings from the DUTRENEO trial, which evaluated the role of predictive biomarkers in guiding neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). Register today. 
|
|
Today’s Big NewsApr 18, 2025 |
|
Thursday, April 22, 2025 | 11am ET / 8am PT Digital transformation is the way of the future, but knowing where and how to start the journey toward digital evolution can be challenging. Join us for key insights on digital strategies that can help you overcome the inefficiencies in traditional methods of process development and biomanufacturing. Register now. 
|
|
| By Nick Paul Taylor Alis Biosciences has made a pitch to the hundreds of biotechs that are valued at less than the cash they have in the bank. The investment fund is proposing to buy the companies and return most of their cash to shareholders, offering them an alternative to exits such as reverse mergers and liquidations. |
|
|
|
By Nick Paul Taylor The U.S. government has pulled the rug out from under Pluri Biotech’s PLX-R18 cell therapy. Having put up funding to help bring the candidate to market, the government terminated the contract in a move that Pluri believes “may reflect broader federal budgetary and administrative adjustments." |
By Nick Paul Taylor VelaVigo Bio has landed its second deal in six months, offloading ex-China rights to a bispecific to Ollin Biosciences for up to $440 million. |
Sponsored by Ohio Discovery Corridor CTI grew from a Cincinnati startup to a global leader in clinical research. CEO Tim Schroder shares insights on its success and what’s next. |
|
Developing next-generation AI models capable of predicting disease progression and treatment response in multiple sclerosis. Learn more. 
|
|
By Gabrielle Masson Biotechs will need to be strategic to achieve “tariff-era success” as the sector enters an “America-first resurgence,” according to a new report from PitchBook. Companies focused on AI integration and manufacturing innovation are expected to win out, according to the firm. |
Sponsored by TriNetX, Inc. Discover how AI and RWD are transforming drug development by optimizing clinical trial protocols, enhancing recruitment, and accelerating timelines. |
By Gabrielle Masson After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and consider other paths to market, The Wall Street Journal reports. |
By Darren Incorvaia,Zoey Becker Just a few weeks after closing a $155 million series B, RNA editing biotech AIRNA is bringing an experienced gene therapy developer on board to help get the company’s first candidate into the clinic. |
By Fraiser Kansteiner In an interview with BMO Capital Markets, a prominent former FDA official has sounded the alarm about the potential for mass layoffs at the agency to disrupt the agency's drug review process. The threat, which would be particularly pronounced for rare disease and cell and gene therapy programs, could set in as early as 2026. |
By Darren Incorvaia An “inverse vaccine” that delivers deactivated allergens to the liver was able to reduce reactions in mice with allergic asthma for at least a year after treatment. Should the approach translate to humans, people with allergies may one day be able to take a vaccine that protects them from dangerous allergic reactions. |
By Ayla Ellison,Fraiser Kansteiner This week on “The Top Line,” we unpack the latest tariffs from the Trump administration and their potential impact on the life sciences industry. |
By Conor Hale The company described it as the first regulatory green light for a developer of wireless mind-reading tech. |
By Noah Tong The Supreme Court is set to hear a case about the Affordable Care Act preventive services April 21. If the coverage requirement is overturned, advocacy groups believe the ruling will lead to more preventable deaths. |
By Angus Liu The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. The European Commission has approved Eisai and Biogen's Leqembi in Alzheimer's disease. Kyowa Kirin has finished the build-out of a Japanese biologics plant. And more. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we unpack the latest tariffs from the Trump administration and their potential impact on the life sciences industry. |
|
|---|
|
|
|
Wednesday, April 23, 2025 | 11am ET / 8am PT Commissioning and qualification (C&Q) are critical processes within pharmaceutical manufacturing. Join us for this valuable webinar to learn about today’s top challenges and the key strategies for overcoming them. 
|
|
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
Whitepaper Avoid costly mistakes and ensure your clinical development program meets the highest standards by reading WCG’s whitepaper on Imaging Core Labs, Endpoint Adjudication Committees (EAC), and other safety reviews. Sponsored by: WCG |
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
